Molecular Formula | C14H19BCl2N2O4 |
Molar Mass | 361.03 |
Density | 1.306 |
Melting Point | >142°C (subl.) |
Water Solubility | DMSO (Sparingly), Methanol (Slightly) |
Appearance | Shape Solid Color White to Pale Yellow |
pKa | 9.67±0.43(Predicted) |
Storage Condition | -20°C Freezer |
Use | On November 20, 2015, the US FDA approved the launch of the new drug Isazomi (Ixazomib) capsule developed by Millennium (Millennium) Pharmaceutical Company under Takeda, Japan, under the trade name Ninlaro. Isazomil is an oral proteasome inhibitor that works by inhibiting the enzyme activity of multiple myeloma cells to prevent the growth and survival of cancer cells. Isazomil is combined with lenalidomide and dexamethasone Treatment of treated patients with multiple myeloma. Multiple myeloma is a rare cancer. There are about 20,000 new cases in the United States every year and about 114,000 in the world. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.77 ml | 13.849 ml | 27.699 ml |
5 mM | 0.554 ml | 2.77 ml | 5.54 ml |
10 mM | 0.277 ml | 1.385 ml | 2.77 ml |
5 mM | 0.055 ml | 0.277 ml | 0.554 ml |